Enlivex Prices $7.5M Staged Registered Direct Offering at 10.5% Premium, With Warrants and 5% Revenue Share
ENLV is trading near its 52-week low of $1.18 (10% below the low) on light trading volume (0.3× avg).
Summary
Enlivex priced a $7.5M registered direct offering at $1.315 per share plus a $1.578 warrant — a 10.5% premium to the prior close — funded with $500,000 upfront and ten $700,000 monthly closings, with qualifying investors also receiving 5% of future licensing and asset-sale proceeds.
Key Events · Financing and Capital Events · ENLV
-
Staged $7.5M Registered Direct Offering
A securities purchase agreement signed November 14, 2026 covers $7,500,000 of ordinary shares (or pre-funded warrants) plus accompanying ordinary warrants at a combined $1.315 per share.
-
Priced at 10.5% Premium
The $1.315 combined price represents a 10.5% premium to the Nasdaq official closing price on November 13, 2026; the warrants carry a $1.578 strike, are immediately exercisable and expire in three years.
-
Monthly Closing Schedule
The initial closing, expected on or about November 17, 2026, brings in $500,000, followed by $700,000 at each of ten monthly closings from December 1, 2026 through about September 1, 2027; some closings may wait on shareholder approval of an authorized share increase.
-
Investors Get 5% of Deal Proceeds
Qualifying investors receive 5% of licensing, collaboration and royalty payments for five years and 5% of clinical-asset sale or license proceeds for 24 months, forfeited if they fund less than $850,000.
Analysis · ENLV · Crypto Assets
Enlivex is raising $7.5M in a registered direct offering priced at $1.315 per share plus an accompanying warrant — a 10.5% premium to the November 13 Nasdaq close, meaning buyers paid up rather than demanding a discount. The money arrives in slices: $500,000 at the initial closing around November 17, then $700,000 a month for ten months through roughly September 1, 2027, with later closings subject to delay until shareholders approve an increase in authorized share capital. Each unit also carries a warrant struck at $1.578 that would add about $9.0M more if exercised in full for cash, though nothing guarantees exercise. The unusual part is the side payment: qualifying investors get 5% of licensing, collaboration and royalty receipts for five years and 5% of any sale or exclusive license of the clinical assets for 24 months — a claim on future Allocetra™ deal economics that ordinary shareholders do not get. Against a market cap of roughly $1.8M, this raise is large relative to the company, and it lands while the stock trades near its 52-week low and after a Nasdaq delisting notice on October 27, so the capital is survival money as much as growth money.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $1.06 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $1.18 to $434.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.